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Background
Sjogrens syndrome (SS) is a chronic autoimmune disorder,
characterised by lymphocytic infiltration resulting in exo-
crine gland destruction and other extra-glandular manifes-
tations [1]. Currently there is no definitive diagnostic test,
and the immuno-pathology is not fully understood.
Recently focus has shifted to investigating microRNAs
(miRs) in an effort to understand the mechanisms contri-
buting to disease pathogenesis. MiRs are short non-coding
RNA sequences, which regulate gene expression post-
transcriptionally [2]. Of note, miRs have been identified as
key regulators of immune function in a variety of autoim-
mune conditions [2]. The hypothesis of this project is that
alterations in expression of specific miRs which regulate
genes relating to inflammation and immunity may play a
role in the pathology of the disease.
Methods
A microRNA screen had been conducted in peripheral
blood mononuclear cells (PBMCs) from healthy controls
and SS patients. From this screen a set of microRNAs
were analysed by bioinformatics using online platforms
including miRWalk, MiRDB and miRanda Tools. Primers
were designed and optimised by PCR for the miRs and
their predicted gene targets. As part of ongoing work in
the lab PBMCs were isolated and transfected with a
sequence that mimics miR-155 (a pro-inflammatory miR).
The effect miR-155 on target genes was analysed qPCR.
Results
Bio-informatic studies identified several novel miRs
whose expression is altered in SS patients compared to
healthy controls. Two miRs that were focused on were
down-regulated in the patient sample and are hsa-miR-
132-3p and hsa-miR-4535 and their target genes are
ESRRG (Estrogen related receptor gamma) and ATRN
(Attractin) respectively; and one up-regulated miR which
is Hsa-miR-185-3p and its target gene is IRF5 (Interferon
regulatory factor 5). Primers for these novel miRs and
gene targets were optimised.
Conclusions
Since these specific miRs have altered expression in SS
patients, and have a direct effect on inflammatory genes,
this indicates that these miRs may have biomarker poten-
tial and further study of these miRs might increase our
understanding of the underlying pathology of Sjogrens
syndrome and other autoimmune diseases.
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